Vimarsana
Biggest News Aggregation in the World

Page 9 - Nasdaq Caba News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Caba. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Caba Today - Breaking & Trending Today

Cabaletta Bio Inc. (CABA): Investing has never been easier - Vimarsana News

Cabaletta Bio Inc. (CABA): Investing has never been easier

Cabaletta Bio Inc. (CABA) is priced at $0.87 after the most recent trading session. At the very opening of the session, the stock price was $0.89 and reached a high price of $0.9325, prior to closing the session it reached the value of $0.94. The stock touched a low price of $0.80.Recently in News o

Cabaletta Bio Presents New Interim Data from the - Vimarsana News

Cabaletta Bio Presents New Interim Data from the

PHILADELPHIA, Sept. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and...

Cabaletta Bio Inc. (CABA): Up ahead of its competition - Vimarsana News

Cabaletta Bio Inc. (CABA): Up ahead of its competition

Cabaletta Bio Inc. (CABA) is priced at $1.25 after the most recent trading session. At the very opening of the session, the stock price was $1.89 and reached a high price of $2.10, prior to closing the session it reached the value of $1.90. The stock touched a low price of $1.10.Recently in News on

Cabaletta Bio (NASDAQ:CABA) Downgraded to "Hold" at Zacks Investment Research - Vimarsana News

Cabaletta Bio (NASDAQ:CABA) Downgraded to "Hold" at Zacks Investment Research

Cabaletta Bio (NASDAQ:CABA – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports. According to Zacks, “Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered […]

Cabaletta Bio (NASDAQ:CABA) Upgraded by Zacks Investment Research to Buy - Vimarsana News

Cabaletta Bio (NASDAQ:CABA) Upgraded by Zacks Investment Research to Buy

Cabaletta Bio (NASDAQ:CABA – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Wednesday, Zacks.com reports. The brokerage currently has a $1.50 target price on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 17.19% from the stock’s […]